- Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. Erlichman, C., Hidalgo, M., Boni, J.P., Martins, P., Quinn, S.E., Zacharchuk, C., Amorusi, P., Adjei, A.A., Rowinsky, E.K. J. Clin. Oncol. (2006)